Captor Therapeutics Spolka Akcyjna
CTX.WA · WSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | -0.09 | -2.04 | -0.22 |
| FCF Yield | -16.27% | -11.88% | -3.57% | -4.53% |
| EV / EBITDA | -4.96 | -6.06 | -21.36 | -25.91 |
| Quality | ||||
| ROIC | -61.35% | -96.63% | -35.84% | -23.03% |
| Gross Margin | 40.59% | 52.28% | 77.21% | 81.41% |
| Cash Conversion Ratio | 0.82 | 0.74 | 0.64 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | 20.00% | 49.06% | – | – |
| Free Cash Flow Growth | 41.93% | -131.58% | 29.02% | -4,061.83% |
| Safety | ||||
| Net Debt / EBITDA | 1.02 | 1.11 | 2.27 | 4.50 |
| Interest Coverage | -102.43 | -226.06 | -66.26 | -79.27 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 779.48 | -29.24 | -365.96 | -59.03 |